Plasma low-density lipoprotein reduction and structural effects on coronary atherosclerotic plaques by atorvastatin as clinically assessed with intravascular ultrasound radio-frequency signal analysis: A randomized prospective study

Yokoyama, Masaki; Komiyama, Nobuyuki; Courtney, Brian K.; Nakayama, Takashi; Namikawa, Susumu; Kuriyama, Nehiro; Koizumi, Tomomi; Nameki, Mizuo; Fitzgerald, Peter J.; Komuro, Issei

doi:10.1016/j.ahj.2005.03.059

Cited by 48 publications

(35 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, several studies that used 3-dimensional IVUS to evaluate changes in coronary plaques after long-term statin therapy showed decreases in atheroma volume. 12,[20][21][22] Our present results show a continuous reduction in atheroma volume under statin treatment from baseline to week 80 (Figure 6), which suggests that lipid-lowering treatment with statins may be able to regress atherosclerosis in coronary disease patients over time; in other words, a late benefit of statin therapy. In the present study, the time course of plaque color change and that of volumetric change differed.…”

Section: Early and Late Benefit Of Statin Therapymentioning

confidence: 65%

Qualitative and Quantitative Changes in Coronary Plaque Associated With Atorvastatin Therapy

Hirayama

Saito

Ueda

et al. 2009

Circ J

View full text Add to dashboard Cite

Circ J 2009; 73: 718 -725 here have been many reports that intensive lowering of low-density lipoprotein-cholesterol (LDL-C) with 3-hydroxy-3-methylglutaryl-coenzyme A (HMGCoA) reductase inhibitors (statins) is effective in preventing cardiovascular events. [1][2][3] Although the mechanism by which statins confer cardiovascular benefit is not precisely understood, regression of coronary plaque volume and reduction of plaque vulnerability are presumed to play important roles. Angioscopic observations have shown that the presence of yellow plaque is associated with unstable symptoms, which suggests that as plaques become more yellow in appearance, they also become more prone to rupture. [4][5][6] Editorial p 628Angioscopy is used to assess plaque vulnerability on the basis of its color and the presence of thrombi. 7,8 Angioscopy gives a full-color, 3-dimensional perspective of the intracoronary surface morphology, and reasonably accurate information regarding a specific lesion, if performed by trained technicians. Intravascular ultrasound (IVUS) is an alternative imaging modality that provides real-time tomographic images of blood vessels on a monitor. It generates information on vessel wall structure, atheroma volume, and the echogenicity of plaque, which is amenable to qualitative and quantitative analysis and can be used to evaluate plaque regression. 9 The effects of statins on coronary plaque have been evaluated by angioscopy, as well as IVUS, in patients with hypercholesterolemia. Using angioscopy, Takano et al demonstrated that the grade of yellow color decreased during statin therapy, 10 and Nissen et al 11 and Okazaki et al 12 used IVUS to investigate the effects of statins on atheroma volume. However, because no study has serially monitored the coronary plaques of patients receiving statin therapy using both angioscopy and IVUS, the relationship between changes in plaque color and changes in atheroma volume has not been elucidated. Therefore, we used both imaging modalities concurrently to investigate the qualitative and quantitative changes over time in coronary plaques in patients receiving atorvastatin therapy to reduce LDL-C levels to ≤100 mg/dl. Methods Study PopulationPatients with coronary artery disease (CAD) complicated by hypercholesterolemia, with a fasting LDL-C level (Received August 10, 2008; accepted December 2, 2008; released online February 18, 2009

show abstract

Section: Early and Late Benefit Of Statin Therapymentioning

confidence: 65%

Qualitative and Quantitative Changes in Coronary Plaque Associated With Atorvastatin Therapy

Hirayama

Saito

Ueda

et al. 2009

Circ J

View full text Add to dashboard Cite

show abstract

“…This dose of pitavastatin still produced a significant reduction of the LDL-C level (33.2% reduction), which was equivalent to that of previous trials with other statins in Japan. [15][16][17][18][19] The PVI was significantly reduced in the pitavastatin group, and there were significant positive correlations between the percent change in PVI and both the follow-up LDL-C level and percent change in LDL-C level. In a recent observational study, von Birgelen et al reported a positive correlation between the mean LDL-C level (the mean between baseline and follow-up LDL-C levels) and the annual change in plaque + media size of the LMCA.…”

Section: Discussionmentioning

confidence: 87%

Impact of Lipid-Lowering Therapy With Pitavastatin, a New HMG-CoA Reductase Inhibitor, on Regression of Coronary Atherosclerotic Plaque A 3-Dimensional Intravascular Ultrasound Study

Takashima

Yasukawa²,

Waseda

et al. 2007

Circ J

View full text Add to dashboard Cite

“…The importance of inhibition of inflammation in tissues is clear from the fact that inflammation is involved in vulnerable plaque, and it was surmised that the possibility that statins 24 Takano et al 25 Takarada et al 26 Toi et al 27 Imaging …”

Section: Pleiotropic and Anti-inflammatory Effects Of Statinsmentioning

confidence: 99%

“…In the CPLASS (Coronary PLAque stabilization by Statin Study), 24 the integrated backscatter (IB) value of IB-IVUS was used as the endpoint to compare an atorvastatin 10 mg group and a control group over a 6-month period. The results showed that the IB value increased depending on the percent decrease in LDL-C; that is, the plaque stabilized.…”

Section: Can Intensive Lipid-lowering Therapy Usingmentioning

confidence: 99%

Clinical Significance of Intensive Lipid-Lowering Therapy Using Statins in Patients With Coronary Artery Disease

Miyauchi

Daida

2010

Circ J

View full text Add to dashboard Cite

Plasma low-density lipoprotein reduction and structural effects on coronary atherosclerotic plaques by atorvastatin as clinically assessed with intravascular ultrasound radio-frequency signal analysis: A randomized prospective study

Cited by 48 publications

References 24 publications

Qualitative and Quantitative Changes in Coronary Plaque Associated With Atorvastatin Therapy

Qualitative and Quantitative Changes in Coronary Plaque Associated With Atorvastatin Therapy

Impact of Lipid-Lowering Therapy With Pitavastatin, a New HMG-CoA Reductase Inhibitor, on Regression of Coronary Atherosclerotic Plaque A 3-Dimensional Intravascular Ultrasound Study

Clinical Significance of Intensive Lipid-Lowering Therapy Using Statins in Patients With Coronary Artery Disease

Contact Info

Product

Resources

About